- CEO
- Yang Yang
- Full Time Employees
- 2,298
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Building A1, Shibuya Science and Technology Industrial Park Changsha HU China 410205
- IPO Date
- Oct 10, 2017
- Business
- Hunan Jiudian Pharmaceutical Co., Ltd. (300705.SZ) researches, develops, produces, and sells pharmaceutical products including finished dosage forms, active pharmaceutical ingredients (APIs), excipients, Chinese traditional medicines, and nutritional supplements primarily in China and internationally; its core offerings encompass analgesic drugs such as loxoprofen sodium gel plaster and ketoprofen gel plaster, cardio-cerebrovascular medications like rosuvastatin calcium tablets, anti-infective agents, anti-allergic products including ebastine tablets, digestive system treatments such as pantoprazole sodium enteric tablets and rabeprazole sodium enteric tablets, urinary system drugs, respiratory medicines, gynecological products, and supplements like ferrous succinate tablets and acetylcysteine granules, with 24 finished products having passed drug consistency evaluation and specialized capabilities in high-end formulations including transdermal drug delivery, controlled release, tablets, capsules, granules, oral solutions, syrups, suspensions, cataplasms, and injections; the company also provides CMO/CDMO services and operates through subsidiaries such as Hunan Jiudian Hongyang Pharmaceutical Co., Ltd. for APIs and excipients, Hunan Pudao Pharmaceutical Technology Co., Ltd. for CXO services, and others focused on wholesale, retail, and e-commerce of medicines. Founded in 2001 and headquartered in Changsha, Hunan Province, China, the company employs nearly 1,900 people, maintains multiple GMP-certified production lines, and exports to over 60 countries including the US, South Korea, and Europe, targeting hospitals, pharmacy chains, and global clients with a focus on high-tech generic drugs, innovative drugs, patented medicines, and percutaneous administration platforms. Recent developments include ranking 76th on the Hunan Top 100 Manufacturing Enterprises list in 2024, a record high reflecting innovation-driven growth and annual sales of nearly 1.6 billion yuan from core anti-inflammatory patches; obtaining a registration certificate in 2025 for polyacrylic acid solution pharmaceutical excipient from its subsidiary Jiudian Hongyang; securing clinical trial approval for PDX-04 in acute gout attacks and a drug registration certificate for a gastric ulcer treatment; completing clinical research and production filing for innovative TCM drug Jiaoqi Zhitong Gel Patch alongside chemical drug advancements; inking a strategic licensing deal in early 2024 with Zonsen PepLib Biotech for preclinical dual-functional peptide PL054 offering up to 560 million yuan in milestones; proposing to acquire a 10% stake in Nuona Pharmaceuticals using 46.58 million yuan to strengthen control; forming a strategic cooperation with Jinying Jiahe for health consulting; passing joint inspections by Fujian and Hunan drug administrations in 2025; and expanding global partnerships at CPHI Shanghai 2025 while advancing intelligent manufacturing as a Hunan Advanced-Level Intelligent Factory.